Fact check
A result can be real and still need context. Check the people enrolled, the treatment comparison and the meaning of the average.
Ask which published study supports the claim.
Ask whether the study group resembles the people the service is talking about.
Ask what happened in the group that did not get the drug.
Check what visits and help were part of the study, then ask what the proposed care includes.
The adults enrolled in SURMOUNT-1 had no diabetes; they had obesity, or overweight along with a related health problem.
The study compared groups taking different strengths of tirzepatide.
Over 72 weeks, average weight loss was about 15% in the lowest-strength group and about 21% in the highest-strength group.
The group given a dummy shot lost about 3%.
The medicine’s maker supported this trial; participants had regular visits and received help with food choices and activity.
Those are study averages, not a promise about your result. Ask the person treating you what range is realistic for you and how progress will be reviewed.
As of September 26, 2026.
Check the product, its approval and who made it. For a compounded product, the medicine is made by a pharmacist or doctor in response to an order.
No: approved Zepbound (tirzepatide) also comes in small medicine bottles, called vials.
The container alone does not identify who made the medicine.
As of September 26, 2026.
For generic tirzepatide, the Food and Drug Administration (FDA) had granted no approvals as of September 26, 2026.
As of September 26, 2026.
Medicine made to fulfill an order has no FDA approval.
As of September 26, 2026.
No: Mounjaro (tirzepatide) has approval for controlling blood sugar in type 2 diabetes.
Its approved uses also include reducing the risk of heart attack, stroke and death due to heart or blood-vessel disease.
That approval covers adults at high risk of those problems who have type 2 diabetes.
Zepbound is the tirzepatide brand with a weight-control approval.